Filing Flows › Comparisons › ENTA vs OCUL
Enanta Pharmaceuticals vs Ocular Therapeutix: ENTA and OCUL compared
Enanta Pharmaceuticals is the larger company: $14.4M of revenue in its latest quarter (Q3 FY26) against $13.5M for Ocular Therapeutix (Q2 2026). Ocular Therapeutix is growing faster (+0.1% against -22% a year earlier). Enanta Pharmaceuticals is more profitable, with an operating margin of -120.0% against -609.3%.
Where the money goes: ENTA and OCUL
Enanta Pharmaceuticals (ENTA) · Q3 FY26
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
Ocular Therapeutix (OCUL) · Q2 2026
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
| Enanta Pharmaceuticals (ENTA) | Ocular Therapeutix (OCUL) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q2 2026 |
| Revenue | $14.4M | $13.5M |
| Revenue growth, Y/Y | -22% | +0.1% |
| Operating margin | -120.0% | -609.3% |
| Net earnings | −$19.5M | −$78.8M |
| Net margin | -135.8% | -584.5% |
| Operating cash flow | −$10.0M | −$67.3M |
Questions
Which is bigger, Enanta Pharmaceuticals or Ocular Therapeutix?
Enanta Pharmaceuticals is the larger company: $14.4M of revenue in its latest quarter (Q3 FY26) against $13.5M for Ocular Therapeutix (Q2 2026).
Is Enanta Pharmaceuticals or Ocular Therapeutix growing faster?
Ocular Therapeutix is growing faster (+0.1% against -22% a year earlier).
Which is more profitable, Enanta Pharmaceuticals or Ocular Therapeutix?
Enanta Pharmaceuticals is more profitable, with an operating margin of -120.0% against -609.3%.
More: Enanta Pharmaceuticals earnings · how Enanta Pharmaceuticals makes money · Ocular Therapeutix earnings · how Ocular Therapeutix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 3, 2026). Fiscal quarters can end on different dates. Not investment advice.